NO20072998L - Stabilisering av glukokortikoidestere med syrer - Google Patents

Stabilisering av glukokortikoidestere med syrer

Info

Publication number
NO20072998L
NO20072998L NO20072998A NO20072998A NO20072998L NO 20072998 L NO20072998 L NO 20072998L NO 20072998 A NO20072998 A NO 20072998A NO 20072998 A NO20072998 A NO 20072998A NO 20072998 L NO20072998 L NO 20072998L
Authority
NO
Norway
Prior art keywords
stabilization
acids
glucocorticoid
esters
glucocorticoid esters
Prior art date
Application number
NO20072998A
Other languages
English (en)
Norwegian (no)
Inventor
Dirk Mertin
Gert Daube
Iris Heep
Georg Schulte
Ulrike Umgelder
Ernst Bottcher
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35758903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072998(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102005055385A external-priority patent/DE102005055385A1/de
Priority claimed from DE200510055386 external-priority patent/DE102005055386A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of NO20072998L publication Critical patent/NO20072998L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
NO20072998A 2004-12-09 2007-06-12 Stabilisering av glukokortikoidestere med syrer NO20072998L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102004059220 2004-12-09
DE102005055385A DE102005055385A1 (de) 2004-12-09 2005-11-17 Arzneimittel zur hygienischen Applikation im Ohr
DE200510055386 DE102005055386A1 (de) 2005-11-17 2005-11-17 Stabilisierung von Glucocorticoidestern mit Säuren
PCT/EP2005/012977 WO2006061155A2 (de) 2004-12-09 2005-12-03 Stabilisierung von glucocorticoidestern mit säuren

Publications (1)

Publication Number Publication Date
NO20072998L true NO20072998L (no) 2007-06-12

Family

ID=35758903

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072998A NO20072998L (no) 2004-12-09 2007-06-12 Stabilisering av glukokortikoidestere med syrer

Country Status (14)

Country Link
US (2) US20090239835A1 (de)
EP (1) EP1827498A2 (de)
JP (1) JP5002462B2 (de)
KR (1) KR101217680B1 (de)
AU (1) AU2005313601B2 (de)
BR (1) BRPI0518853A2 (de)
CA (1) CA2591296A1 (de)
CR (1) CR9164A (de)
HK (1) HK1117044A1 (de)
IL (1) IL183743A0 (de)
MX (1) MX2007006908A (de)
NO (1) NO20072998L (de)
NZ (1) NZ555641A (de)
WO (1) WO2006061155A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007055341A1 (de) * 2007-11-19 2009-05-20 Bayer Animal Health Gmbh Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
GR20090100230A (el) 2009-04-14 2010-11-18 Casso Pharmaceuticals Ε.Π.Ε, Απο του στοματος εναιωρημα οξικης δεξαμεθανοζης-συνθεση καλυψης γευσης της δεξαμεθανοζης
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
KR20210135003A (ko) * 2011-05-15 2021-11-11 에이세러스 바이오파마 인크. 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
AR096459A1 (es) * 2013-06-03 2015-12-30 Tolmar Inc Composiciones de corticosteroides y método de fabricación
US10111956B2 (en) 2013-06-03 2018-10-30 Tolmar, Inc. Corticosteroid compositions
KR20190024983A (ko) 2016-06-29 2019-03-08 오토노미, 인코포레이티드 트리글리세라이드 귀 제제 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6032714B2 (ja) 1978-07-04 1985-07-30 新日本製鐵株式会社 表面処理鋼板
JPS5524131A (en) * 1978-08-09 1980-02-21 Nippon Redarii Kk Synthetic adrenal cortical hormone preparation ointment and its base
JPS6028923B2 (ja) 1979-05-28 1985-07-08 三井化学株式会社 エレクトレツト化捲縮繊維の製法
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
JPS6032714A (ja) * 1983-08-01 1985-02-19 Teijin Ltd 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物
DE3333719A1 (de) * 1983-09-17 1985-04-04 Bayer Ag Loesungen milchsaurer salze von piperazinylchinolon- und piperazinyl-azachinoloncarbonsaeuren
GB8420771D0 (en) * 1984-08-15 1984-09-19 Efamol Ltd Treatment of skin disorders
JPS61167614A (ja) * 1985-01-22 1986-07-29 Mitsubishi Yuka Yakuhin Kk ステロイド含有軟膏剤
DE3537761A1 (de) * 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
DE3713672A1 (de) * 1987-04-24 1988-11-17 Bayer Ag Verfahren zur herstellung von parenteral verabreichbaren chinoloncarbonsaeuren
US5444096A (en) * 1989-06-02 1995-08-22 Helene Curtis, Inc. Stable anhydrous topically-active composition and suspending agent therefor
DE19500784A1 (de) * 1995-01-13 1996-07-18 Bayer Ag Enrofloxacin-Injektions- oder Infusionslösungen
CA2176298C (en) * 1995-06-27 2009-01-27 Dennis D. Copeland A single high dose fluoroquinolone treatment
US5972920A (en) * 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds

Also Published As

Publication number Publication date
WO2006061155A2 (de) 2006-06-15
JP2008522997A (ja) 2008-07-03
KR101217680B1 (ko) 2013-01-02
CR9164A (es) 2008-03-03
AU2005313601B2 (en) 2012-05-24
KR20070086690A (ko) 2007-08-27
WO2006061155A3 (de) 2006-08-31
AU2005313601A1 (en) 2006-06-15
CA2591296A1 (en) 2006-06-15
US20110301135A1 (en) 2011-12-08
EP1827498A2 (de) 2007-09-05
JP5002462B2 (ja) 2012-08-15
BRPI0518853A2 (pt) 2008-12-09
HK1117044A1 (en) 2009-01-09
US20090239835A1 (en) 2009-09-24
NZ555641A (en) 2010-10-29
MX2007006908A (es) 2007-08-03
IL183743A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
NO20072998L (no) Stabilisering av glukokortikoidestere med syrer
MY166613A (en) Glycerol levulinate ketals and their use
TN2011000346A1 (en) Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
WO2010057203A3 (en) Hdl particles for delivery of nucleic acids
MX2014004725A (es) Formulaciones de etanercept estabilizadas con aminoacidos.
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
EA201290389A8 (ru) Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени
NO20090596L (no) Antivirale fosfinatforbindelser
WO2008036932A3 (en) Compositions and methods comprising boswellia species
EA201500650A1 (ru) Фенилацетат l-орнитина и способы его получения
WO2006078659A3 (en) Stable prostaglandin-containing compositions
WO2010146172A3 (en) New synthetic route for the preparation of alpha-amino boronic esters
ATE529404T1 (de) Phenoxyessigsäuren als ppar-delta-aktivatoren
ZA200810317B (en) High-strength,low temperature stable herbicidal formulations of fluroxypyr esters
MX348402B (es) Conversión de 5-(clorometil)-2-furaldehído en ácido 5-metil-2-furoico y sus derivados.
DK1608346T3 (da) Lægemiddeltilförselssammensætninger af alfa-hydroxysyreester og fremgangsmåder til anvendelse heraf
TNSN07435A1 (en) Novel piperidine carboxylic acid amide derivatives
WO2007079180A3 (en) Inhibitors of fatty acid amide hydrolase
HK1112592A1 (en) Composition for reducing the exudation of serum proteins
BRPI0814115B8 (pt) composição farmacêutica compreendendo o composto 11-deóxi-prostaglandina e método para estabilizar o composto
EA200870543A1 (ru) Нежелательные примеси к донепезилу
CY1112501T1 (el) Φαρμακευτικες συνθεσεις περιεχουσες λεφλουνομιδη
WO2005087718A3 (de) Carbodiimide mit thiocarbamidsäureestergruppen
UA88663C2 (en) Stabilisation of glucocorticoid esters with acids
CY1107277T1 (el) Βενζισοξαζολες

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

FC2A Withdrawal, rejection or dismissal of laid open patent application